Trial Profile
An Open-Label, Single-Dose Study to Evaluate the Effects of Age and Sex on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Bullous pemphigoid; COVID 2019 infections; Eczema; Female genital diseases; Hidradenitis suppurativa; Immunodeficiency disorders; Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Amgen; Celgene Corporation
- 14 Jul 2012 New trial record